PMV Pharmaceuticals, Inc
PMV Pharmaceuticals is dedicated to developing targeted therapies for cancer by focusing on mutant p53 proteins. With over 40 years of experience, the company employs a unique approach to structurally correct mutated p53, aiming to restore its tumor suppressing function. Their mission is to create meaningful outcomes for patients living with cancer through precision oncology and innovative small-molecule therapies.
Industries
Nr. of Employees
medium (51-250)
PMV Pharmaceuticals, Inc
Patents
Products
Selective p53 Y220C reactivator (oral small molecule, clinical-stage)
An investigational, orally administered small molecule designed to bind and stabilize the p53 Y220C mutant, restoring tumor-suppressor function; being evaluated in Phase 1/2 studies for patients with tumors harboring the p53 Y220C mutation. The program has received FDA Fast Track designation.
Selective p53 Y220C reactivator (oral small molecule, clinical-stage)
An investigational, orally administered small molecule designed to bind and stabilize the p53 Y220C mutant, restoring tumor-suppressor function; being evaluated in Phase 1/2 studies for patients with tumors harboring the p53 Y220C mutation. The program has received FDA Fast Track designation.
Services
End-to-end internal R&D activities including target-specific screening, medicinal chemistry optimization, and selection of clinical candidates.
Execution of GLP-compliant safety and toxicology studies to support regulatory filings.
Sponsorship and operational management of Phase 1/2 multicenter studies including safety, PK, PD, and efficacy endpoints.
Mechanisms to provide investigational product and support for investigator-initiated clinical studies.
End-to-end internal R&D activities including target-specific screening, medicinal chemistry optimization, and selection of clinical candidates.
Execution of GLP-compliant safety and toxicology studies to support regulatory filings.
Sponsorship and operational management of Phase 1/2 multicenter studies including safety, PK, PD, and efficacy endpoints.
Mechanisms to provide investigational product and support for investigator-initiated clinical studies.
Expertise Areas
- Precision oncology
- Small-molecule drug discovery
- Structure-guided drug design
- Tumor-agnostic therapeutic development targeting gene mutations
Key Technologies
- Structure-based drug design
- Protein–ligand docking
- High-throughput biological screening
- Medicinal chemistry and lead optimization
News & Updates
Financial results and corporate highlights for Q2 2025.
Announcement of participation in upcoming investor conferences.
Financial results and corporate highlights for Q1 2025.
Financial results and corporate highlights for Q2 2025.
Announcement of participation in upcoming investor conferences.
Financial results and corporate highlights for Q1 2025.